Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Commentary on: ‘Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia’

Leukemia volume 30, pages 1636–1637 (2016)Cite this article

Subjects

In this reanalysis of a series of large German acute myeloid leukemia (AML) trials with similar designs, Dr Buchner et al.1 focus on subsets of older patients in an attempt to demonstrate whether planned dose intensity has an effect on survival and other outcomes, independent of patient age. They make the reasonable assumption that medical and biological factors would be similar in ‘younger older’ patients aged ⩾57–<60 years and ‘older older’ individuals aged >60–<63 years, and, in fact, the demographic data from these two groups were very similar. In a unique feature of the study design, the implications of which will be discussed further below, all patients were randomized at the time of study entry to different approaches to dose and schedule of therapy with the plan to analyze the results using the principle of intent to treat (ITT).

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

References

  • Buchner T, Krug UO, Gale RP, Heinecke A, Sauerland C, Haferlach C et al. Age, not therapy-intensity, determines outcomes of adults with acute myeloid leukaemia. Leukemia 2016.

  • Burnett AK, Russell NH, Hills RK, Hunter AE, Kjeldsen L, Yin J et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol 2013; 31: 3360–3368.

    Article  CAS  Google Scholar 

  • Plunkett W, Liliemark JO, Adams TM, Nowak B, Estey E, Kantarjian H et al. Saturation of 1-beta-D-arabinofuranosylcytosine 5’-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy. Cancer Res 1987; 47: 3005–3011.

    CAS  PubMed  Google Scholar 

  • Wheatley K, Hills RK, Burnett AK . Problems with up-front randomization in clinical trials. J Clin Oncol 2006; 24: 5471–5472.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine and Oncology, Wayne State University School of Medicine, Karmanos Cancer Institute, Detroit, MI, USA

    C A Schiffer

Authors
  1. C A Schiffer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C A Schiffer.

Ethics declarations

Competing interests

The author declares no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schiffer, C. Commentary on: ‘Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia’. Leukemia 30, 1636–1637 (2016). https://doi.org/10.1038/leu.2016.141

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2016.141

Search

Advanced search

Quick links